Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Plasma Tests Measure Tumor Load

By HospiMedica staff writers
Posted on 07 Apr 2006
Assays for genetic components of leukemia and lymphoma using blood plasma instead of bone marrow measure "tumor load,” detect blood cancer markers, and assess patient response to therapy.

Leumeta assays, developed by Quest Diagnostics (Lyndhurst, NJ, USA), allow for detection of specific proteins, DNA, RNA, or other molecular targets expressed on or within tumor cells without painful bone marrow extraction. More...
Studies presented at the American Society of Hematology meeting in December 2005 showed that information about tumor load and blood cancer markers of leukemia and lymphoma tumors is contained in blood plasma.

Francis Giles, M.D., professor of medicine and chief of developmental therapies in the department of leukemia at the M.D. Anderson Cancer Center (Houston, Texas, USA), noted, "In an era of increasing focus on targeted therapies, the ability to sequentially obtain so much data from blood plasma specimens is a major help in optimally using the available therapies, and in assessing the efficiency of novel agents. To obtain this data without the need for bone marrow tissue is a major advance.”

The Leumeta assays were developed by a team of researchers at Quest Diagnostics using licensed technology discovered by one of the researchers while previously at M.D. Anderson Cancer Center.



Related Links:
Quest Diagnostics
M.D. Anderson Cancer Center

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Monitor/Defibrillator
Zenix
Immobilization System
Cranial 4Pi Immobilization
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.